Nomura has initiated coverage on Anthem Biosciences with a buy rating and a target price of ₹740 per share, stating that the company is well positioned to capitalise on the rapidly expanding CRDMO (Contract Research, Development and Manufacturing Organisation) opportunity. The brokerage noted that Anthem Bio operates at the intersection of specialty chemistry, fermentation, and biologics, giving it a diversified scientific platform that can scale with global outsourcing demand.
Nomura estimates that the company will deliver sales growth of 14%, 18% and 22% over FY26–28, while earnings are projected to rise by 27%, 21% and 26% during the same period. The near-term topline may moderate, largely due to a high base built over the last two years, but the brokerage expects growth to accelerate again in FY27 and FY28 as capacity additions ramp up and new product launches gather momentum. Steady end-market demand for the company’s key molecules, coupled with a strong pipeline of upcoming launches, reinforces confidence in Anthem Bio’s ability to sustain double-digit growth.
Nomura added that continued expansion in fermentation capacity and early signs of scale benefits in the company’s CDMO vertical strengthen the medium-term outlook. With global customers increasingly shifting projects to India for cost efficiency and technical depth, the brokerage believes Anthem Bio is strategically placed to gain wallet share across multiple client categories.
Disclaimer: The views and recommendations above are those of Nomura. Business Upturn does not endorse them. Please consult a financial advisor before making investment decisions.
